ArticleFrontiers in immunology2026
Case Report: IgG4-related lung disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin G4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory condition, distinct from classical autoimmune disorders, that can affect multiple organs. Pulmonary involvement often presents with non-specific clinical and radiographic features, contributing to high rates of misdiagnosis and underdiagnosis. Here, we report a rare case of IgG4-related lung disease (IgG4-RLD) to enhance clinical awareness. A 71-year-old female presented with cough. Chest computed tomography (CT) revealed an irregular soft tissue mass in the right middle lobe. All autoantibodies tested were negative, and the serum IgG4 level was within the normal range. The patient showed no response to anti-infective and antitussive therapy, with follow-up CT confirming lesion enlargement. A CT-guided percutaneous lung biopsy was subsequently performed. Histopathology demonstrated infiltration of numerous lymphocytes and plasma cells, along with scattered neutrophils. Immunohistochemistry showed a ratio of IgG4-positive to IgG-positive plasma cells of approximately 42%, and demonstrated approximately 30 IgG4-positive plasma cells per high-power field (HPF). The diagnosis of IgG4-RLD was established based on the 2019 ACR/EULAR International Classification Criteria for IgG4-RD. The patient was subsequently treated with oral prednisone, which led to complete resolution of the cough and near-complete regression of the pulmonary lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.